Effects of Celecoxib After Percutaneous Coronary Intervention

Seoul National University Hospital260 enrolled

Overview

Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

260

Conditions

Coronary Arteriosclerosis

Interventions

CelecoxibDRUG

celecoxib: loading and maintenance for 6 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Coronary artery disease with at least 1 de novo lesion greater than 50% stenosis on coronary angiography Exclusion Criteria: * Acute ST elevation MI * Left main disease * Contraindications to aspirin, clopidogrel or celecoxib * Severe congestive heart failure * Expected survival \< 2 years * Hepatic dysfunction * Currently taking NSAIDs or any COX-2 inhibitor * Renal dysfunction * Use of warfarin

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Late luminal loss at 6 months

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.